Compare Gilead Sciences, Inc. (GILD) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Keysight Technologies Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Keysight Technologies Inc trades at $380.3 (market cap $63.79B). The key difference: Gilead Sciences, Inc. is far larger — about 2.9× Keysight Technologies Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Keysight Technologies Inc for 56 Days on average.
| GILD | KEYS | |
|---|---|---|
Market Cap | $182.09B | $63.79B |
Volume | 4,960,247 | 1,435,384 |
Sector | Health | Technology |
52-Week High | $155.80 | $387.90 |
52-Week Low | $116.74 | $159.49 |
Typical Hold Time | 111 Days | 56 Days |
Enterprise Value | $205.15B | $63.93B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Keysight Technologies (KEYS) trades at $381.49, down 1.65% on the day, amid strong fundamental performance with Q2 2026 EPS beating estimates at $3.07. The stock shows a bullish technical trend, trading near the pivot point of $380 with support at $377. Revenue for 2025 reached $5.38B, with net income of $850M, and the company is actively advancing in AI infrastructure and 6G testing, as highlighted in recent product launches and collaborations.
Outlook remains positive with a consensus price target of $416.63, representing a 9.2% upside, supported by accelerating earnings and strong AI demand. Risks include high valuation multiples, such as a P/E of 51.61, and supply constraints that may limit near-term revenue conversion despite surging orders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
